Rhophylac for ITP
Search    
Include All CSL Behring Country Sites

Efficacy

 
Rhophylac® gives platelet levels a lift with proven efficacy.

Rhophylac® is effective in raising platelet counts and preventing excessive bleeding.

A study of 98 adult chronic ITP patients with a platelet count of 30,000 mcg/mL or less were treated with Rhophylac® in a single intravenous (IV) dose of 250 IU (50 mcg/kg body weight). The following results were seen at Day 15:

Primary Response Rates by Baseline Platelet Count at Day 15 (N=98)
  • Overall increase in platelet count at least 20,000/microliter over baseline and up to 30,000/microliter
    • 66% response rate
    • In patients with baseline platelet count of >20,000-30,000/microliter, 89% primary response rate
  • Regression of hemorrhage in patients with bleeding at baseline
    • 88% response rate
  • Increased platelet counts to more than 50,000/microliter
    • 55% response rate
    • 82% response rate in patients with baseline platelet counts of >20,000 to 30,000/microliter

Median time to response was 3 days and median duration of response was 22 days.

How Rhophylac® Works

The mechanism of action is thought to involve the formation of Rh0(D) immune globulin red blood cell complexes, which are preferentially removed by the reticuloendothelial system, particularly the spleen. This leads to an Fc receptor blockade, and as a result antibody-coated platelets are spared. Learn about the Rhophylac® Assurance of Safety.

 

IMPORTANT SAFETY INFORMATION

Rhophylac® is indicated to raise platelet counts in Rh0(D)-positive, non-splenectomized adult patients with chronic immune thrombocytopenic purpura (ITP). For the treatment of ITP, Rhophylac® must be administered IV.

Rhophylac® is contraindicated in individuals with known anaphylactic or severe systemic reaction to human immune globulin products.

Allergic or hypersensitivity reactions may occur with Rhophylac®; early signs of hypersensitivity include generalized urticaria, chest tightness, wheezing, hypotension, and anaphylaxis. Individuals with selective IgA deficiency can develop antibodies to IgA and may develop severe hypersensitivity and anaphylactic reactions. For these individuals, weigh the expected benefits of treatment against the potential risks.

Rhophylac® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

The most serious adverse reactions in patients receiving Rh0(D) immune globulin have been observed in the treatment of ITP. ITP patients being treated with Rhophylac® should be monitored for signs and symptoms of intravascular hemolysis, including back pain, shaking chills, fever, and hemoglobinuria. Potentially serious complications of intravascular hemolysis include clinically compromising anemia, acute renal insufficiency, and, very rarely, disseminated intravascular coagulation, and death.

The most common adverse reactions observed in the treatment of ITP are chills, pyrexia/increased body temperature, and headache. Mild extravascular hemolysis has also been observed. In patients with preexisting anemia, weigh the benefits of Rhophylac® against the potential risk of increasing the severity of the anemia.

Please see full prescribing information.

© 2008 CSL Behring
The product information presented on this site is intended for US residents only.